Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ACUR | Common Stock | Conversion of derivative security | $6.88M | +43M | $0.16 | 43M | Jun 9, 2021 | By Abuse Deterrent Pharma, LLC | F1 | |
holding | ACUR | Common Stock | 8.91M | Jun 9, 2021 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ACUR | Convertible Promissory Note | Conversion of derivative security | -$6.88M | 0 | Jun 9, 2021 | Common Stock | 43M | $0.16 | By Abuse Deterrent Parma, LLC | F1, F2, F3 | |||
holding | ACUR | Warrant to Purchase Common Stock | 1.78M | Jun 9, 2021 | Common Stock | 1.78M | $0.53 | Direct | ||||||
holding | ACUR | Warrant to Purchase Common Stock | 10M | Jun 9, 2021 | Common Stock | 10M | $0.01 | By Abuse Deterrent Parma, LLC | F1 |
Id | Content |
---|---|
F1 | The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
F2 | On the conversion date, $6,000,000 of principal and $877,500 of interest under the note was converted into the Issuer's common stock. For each $0.16 converted, AD Pharma received one share of common stock. |
F3 | This note is convertible, at the election of AD Pharma, at any time prior to repayment of the note and matures on July 1, 2023. |